What the FDA's 2026 Peptide Rules Mean for You

If you're using compounded peptides — or thinking about it — you need to pay attention to what the FDA has been doing. The regulatory landscape for peptides has shifted significantly in 2025 and 2026, and it directly affects which peptides are available, how they're made, and who can prescribe them. This isn't the most exciting topic, but it's one of the most important. The difference between having access to a medication and not having access often comes down to regulatory decisions like these.

What's Changed

The Bulk Drug Substance Lists

Compounding pharmacies don't just make whatever they want. They operate under specific FDA frameworks — Section 503A for traditional pharmacies and Section 503B for outsourcing facilities — and can only compound drugs using ingredients on approved lists. The FDA maintains a "bulk drug substance" list of active ingredients that compounding pharmacies can use. Several peptides have been evaluated for inclusion on this list, and the results haven't always been favorable for patients. Some peptides that were previously compounded with little scrutiny have faced restrictions because they lack sufficient safety data or because they're essentially copies of commercially available products.¹

What This Means in Practice

If you're getting a compounded peptide, the pharmacy may have had to change its formulation or stop offering certain products entirely. This isn't because the peptide is necessarily dangerous — it's because the FDA wants more data before allowing widespread compounding. For patients, this can mean:

• Needing to switch to a branded version (often more expensive)
• Having to find a pharmacy that's still compliant
• Needing updated prescriptions that account for formulation changes

New FDA Approvals (2025-2026)

On the bright side, several new peptide-based medications have been approved or expanded in indications: Vosoritide (Voxzogo) received expanded age-range approval for achondroplasia, giving more patients access to this growth-factor-targeting therapy.² Setmelanotide (Imcivree) got broader obesity indications, expanding beyond its initial approval for rare genetic obesity conditions. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, is expected to receive FDA approval in 2026. Early trial data showed weight loss exceeding both semaglutide and tirzepatide — which would be a significant development.³

The Compounding vs. Brand Name Question

This is where it gets nuanced. The FDA's position is generally that if a commercially manufactured version of a drug exists, compounding pharmacies shouldn't make copies of it (with some exceptions for drug shortages or patient-specific needs). For GLP-1 medications like semaglutide and tirzepatide, this has been a contentious issue. When brand-name versions were in shortage, compounding was widely accepted. As supply has improved, the FDA has started pushing back on compounded versions — even though they're often a fraction of the cost.

When Compounding Is Still Appropriate

The FDA does allow compounding when:

• The patient has a documented allergy to an excipient in the commercial product
• The commercial product is in shortage (check the FDA Drug Shortage Database)
• A specific dose or formulation isn't available commercially
• There's clear medical necessity documented by the prescriber

Documentation Requirements

If you're using compounded peptides, your prescriber should have documented:

• A clear medical necessity rationale
• Informed consent explaining the compounded nature of the product
• A monitoring plan for safety and efficacy
• Outcomes documentation This isn't just bureaucratic paperwork — it protects both you and your provider. If an adverse event occurs, proper documentation demonstrates that appropriate clinical judgment was used.⁴

How to Protect Yourself

Whether you're a patient or a provider, here's how to navigate this landscape: Use PCAB-accredited pharmacies. The Pharmacy Compounding Accreditation Board (PCAB) sets quality standards for compounding pharmacies. Accreditation isn't required, but it's a strong signal of quality and compliance. Check the FDA Drug Shortage Database. If a drug is listed as in shortage, compounding is generally more clearly permissible. The database is updated regularly at fda.gov. Stay informed. The FDA publishes guidance documents and compounding risk reports. Following these isn't exciting reading, but it helps you know what's coming. Report problems. If you have an adverse event with a compounded product, report it through the FDA's MedWatch system. This data helps the FDA make better-informed decisions about what to allow.

What's Coming Next

The FDA is expected to issue additional guidance on peptide compounding later in 2026. The direction seems clear: more oversight, stricter quality requirements, and continued pressure on compounding pharmacies that produce copies of commercially available drugs. For patients who depend on compounded peptides for affordability, this is concerning. The solution isn't less regulation — unsafe compounded drugs are a real problem — but rather better access to affordable branded options and clearer pathways for legitimate compounding. We'll continue to update this article as new regulatory developments emerge. In the meantime, the best thing you can do is stay informed, work with compliant pharmacies and providers, and document everything.

References

1. FDA (2025). Compounding: Bulk Drug Substances. FDA.gov
2. Savarirayan, R., et al. (2023). Once-Daily Vosoritide for Achondroplasia. New England Journal of Medicine, 390(1), 49-59. PubMed: 37952141
3. Jastreboff, A.M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 389(6), 514-526. PubMed: 37366315
4. FDA (2024). Compounding and the FDA: Questions and Answers. FDA.gov